Minghui has reported positive topline outcomes from the Phase III trial of MH004 for treating mild to moderate atopic ...

GLP-1R injectable drugs are effective in treating obesity, but their success points to a gap in the market: oral alternatives ...

Cantargia has commenced an expanded segment of the ongoing Phase I trial of its antibody, CAN10, with the first participant ...

Novocure’s TTFields therapy combined with chemo improved overall survival by 16.2 months compared to 14.16 months with chemo ...

Qatar Foundation member Sidra Medicine has conducted the industry-sponsored ‘sunRIZE’ trial for paediatric congenital ...

The results demonstrate the safety and efficacy of Fasenra in the treatment of acute eosinophilic exacerbations in asthma and ...

The Phase III trial of AXS-12 showed results over placebo as the company looks towards a new drug application for its ...

SELLAS has announced positive data from preclinical studies identifying the ASXL1 mutation as a predictor of response to ...

The Phase I trial of the combination therapy saw a an approximate 66% rate of near-complete remission in its cohort of breast ...

The announcement means the company will be pulling the plug on the CardinALS trial after its ALS drug failed to halt disease ...

Tryptamine Therapeutics (Tryp) has announced the completion of subject dosing in a Phase Ib clinical trial of TRP-8803, for ...

Aulos Bioscience has announced the first patients have been dosed as part of a trial investigating avelumab, marketed as ...